NASDAQ:XCUR Exicure Q4 2025 Earnings Report $2.17 -0.62 (-22.22%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$2.37 +0.20 (+9.22%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Exicure EPS ResultsActual EPS-$0.46Consensus EPS -$18.60Beat/MissBeat by +$18.14One Year Ago EPSN/AExicure Revenue ResultsActual RevenueN/AExpected Revenue$1.64 millionBeat/MissN/AYoY Revenue GrowthN/AExicure Announcement DetailsQuarterQ4 2025Date3/25/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsExicure's next earnings date is estimated for Friday, August 7, 2026, based on past reporting schedules. Conference Call ResourcesSEC FilingEarnings HistoryCompany Profile Exicure Earnings HeadlinesExicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 11, 2026 | finanznachrichten.deExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementJune 10, 2026 | markets.businessinsider.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 10, 2026 | globenewswire.comExicure Regains Nasdaq Compliance After Late Quarterly FilingJune 1, 2026 | tipranks.comExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QJune 1, 2026 | globenewswire.comSee More Exicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email. Email Address About ExicureExicure (NASDAQ:XCUR) is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system. The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies. Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area. Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.View Exicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Okta’s AI Moment May Be Bigger Than Investors RealizeStrategy’s Bitcoin Rally Has a Hidden EngineIs Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big Question Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
